Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

University of Alabama at Birmingham Comprehensive Cancer Center

1824 Sixth Avenue, Wallace Tumor Institute, South Birmingham, AL 35294 - USA

The University of Alabama at Birmingham Comprehensive Cancer Center is the only National Cancer Institute-designated comprehensive cancer center located in a six-state area that includes Alabama, Arkansas, Georgia, Louisiana, Mississippi, and South Carolina.

From bench to bedside, the UAB Comprehensive Cancer Center is at the forefront of improving cancer prevention, diagnosis, and treatment. Researchers have pioneered advances in chemotherapy, surgery, radiotherapy, immunotherapy, and nutrition.

The UAB Comprehensive Cancer Center offers a full array of treatment options from multidisciplinary clinics filled with experts from across cancer fields to the latest technology. The center is home to more than 350 physicians and researchers, many of whom are internationally and nationally recognized for their expertise in oncology. The Cancer Center treats an estimated 5,000 new patients each year.

Website: The University of Alabama at Birmingham Comprehensive Cancer Center

Contact:
Freda Lewis
205-975-3742

Trials at this location:

HCRN-BRE18-334

A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status: Open to Accrual
Read More

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status: Open to Accrual
Read More

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Status: Open to Accrual
Read More

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Status: Open to Accrual
Read More